Keros Therapeutics Reports Q1 Net Loss, Strong Cash Runway into 2028, and Pipeline Progress
KROS is trading near its 52-week low of $10.415 (14% above the low).
Summary
Keros Therapeutics reported an expected Q1 net loss as revenue normalized, but maintains a strong cash position of $281.5 million, providing a runway into mid-2028, alongside positive clinical advancements for its lead product candidates.
Key Events · Earnings and Guidance · KROS
-
Q1 2026 Financial Results
Keros Therapeutics reported a net loss of $23.7 million for the first quarter of 2026, compared to a net income of $148.5 million in Q1 2025. Total revenue for Q1 2026 was $0.4 million, down from $211.2 million in Q1 2025, primarily due to the one-time Takeda upfront payment in the prior year.
-
Strong Cash Position and Runway
The company ended Q1 2026 with $281.5 million in cash and cash equivalents, which management believes is sufficient to fund operations into the first half of 2028.
-
Advancing Clinical Pipeline
Rinvatercept (KER-065) is expected to initiate a Phase 2 clinical trial in DMD in Q3 2026, with initial data anticipated in H1 2027. Plans are also underway to engage regulators for a Phase 2 ALS trial in H2 2026. Partner Takeda is advancing elritercept (KER-050) into a Phase 3 clinical trial for myelodysplastic syndromes.
-
ATM Program Inactive
The At-The-Market (ATM) sales agreement is currently inactive, and no shares were sold under the program during the three months ended March 31, 2026.
Analysis · KROS · Life Sciences
Keros Therapeutics reported a net loss of $23.7 million for Q1 2026, a significant shift from the $148.5 million net income in Q1 2025. This change was anticipated as the prior year's income was largely driven by a one-time $200 million upfront payment from the Takeda license agreement. Despite the current quarter's loss, the company maintains a robust cash position of $281.5 million, which is projected to fund operations into the first half of 2028. This provides a substantial runway for a clinical-stage biotech. The filing also highlights continued clinical progress, with rinvatercept advancing to Phase 2 trials for Duchenne muscular dystrophy (DMD) and amyotrophic lateral sclerosis (ALS), and partner Takeda moving elritercept into a Phase 3 trial for myelodysplastic syndromes. The company's At-The-Market (ATM) program is currently inactive, meaning no new shares were sold in Q1 2026, which removes a potential dilutive overhang.
At the time of this filing, KROS was trading at $11.86 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $237.3M. The 52-week trading range was $10.42 to $22.55. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.